Itoh K, Mizugaki M, Ishida N
Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Japan.
Clin Chim Acta. 1989 May 31;181(3):305-15. doi: 10.1016/0009-8981(89)90236-2.
Preparation of anti-pseudouridine monoclonal antibodies (MoAbs) and their applications for the quantitation of urinary pseudouridine in cancer patients are described. Seven MoAbs were selected. Five MoAbs were specific for pseudouridine and two MoAbs were cross-reactive with uridine. The most specific antibody, APU-6, was used in an enzyme-linked immunosorbent assay (ELISA) to determine urinary pseudouridine. Sensitivity was in the picomole range and the accuracy was nearly equal to that of the high performance liquid chromatography (HPLC) assay. The amount of pseudouridine in the urine of 28 healthy donors was 31.17 +/- 9.94 nmol/mumol creatinine. In 55% (35/63) of patients with cancer, urinary pseudouridine was elevated above the normal mean + 2 SD (51.04 nmol/mumol creatinine). Particularly, all of the patients (15/15) with leukemia and lymphoma had elevated levels of pseudouridine. These results suggest that urinary pseudouridine might be useful as a marker for leukemia and lymphoma.
本文描述了抗假尿苷单克隆抗体（MoAbs）的制备及其在癌症患者尿中假尿苷定量分析中的应用。筛选出了7种单克隆抗体。其中5种单克隆抗体对假尿苷具有特异性，2种单克隆抗体与尿苷有交叉反应。最具特异性的抗体APU-6用于酶联免疫吸附测定（ELISA）以测定尿中的假尿苷。灵敏度在皮摩尔范围内，准确度几乎与高效液相色谱（HPLC）测定法相当。28名健康供体尿液中假尿苷的含量为31.17±9.94 nmol/μmol肌酐。在55%（35/63）的癌症患者中，尿中假尿苷升高至正常均值+2标准差以上（51.04 nmol/μmol肌酐）。特别是，所有白血病和淋巴瘤患者（15/15）的假尿苷水平均升高。这些结果表明，尿中假尿苷可能作为白血病和淋巴瘤的标志物。
